An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model

Alternatives to Laboratory Animals

Volumn 38, Issue 5, 2010, Pages 387-418

  Bailey, Jarrod ^a  

^a New England Anti Vivisection Society   (United States)

Author keywords

Chimpanzee; Hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Pan troglodytes

Indexed keywords

A 831; A 837093; ABT 333; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; AVI 4065; BALAPIRAVIR; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CILUPREVIR; DANOPREVIR; DNA VACCINE; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; IDENIX; IDX 184; ISIS 14803; MIFEPRISTONE; MK 0608; MK 3253; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; R 7128; RECOMBINANT VACCINE; RIBAVIRIN; RO 5024048; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VCH 916;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; ANIMAL WELFARE; ANTIVIRAL ACTIVITY; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CHIMPANZEE; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL ETHICS; MEDICAL RESEARCH; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VACCINE PRODUCTION; VIREMIA; VIRUS GENOME; VIRUS HEPATITIS; VIRUS LIKE AGENT; VIRUS REPLICATION;

HEPATITIS C VIRUS; PAN; PAN TROGLODYTES;

EID: 79251471163     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291003800501     Document Type: Review

References (330)

1. NEAVS (2008). End Chimpanzee Research: Overview - International Bans. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.releasechimps.org/ mission/end-chimpanzee-research/ country-bans (Accessed 20.07.10).
2. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2008). Building an inner sanctuary: Complex PTSD in chimpanzees. Journal of Trauma & Dissociation 9, 9-34.
3. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2009). Developmental context effects on bi-cultural post-trauma self repair in chimpanzees. Developmental Psychology 45, 1376-1388.
4. Sauer, U.G. (2000). Reasons for not using primates in research. [In German] ALTEX 17, 217-220.
5. Thew, M. (2002). Are results of primate research worth the suffering it causes? Nature, London 418, 273.
6. Bailey, J. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA 36, 381-428.
7. Bailey, J., Balcombe, J. & Capaldo, T. (2007). Chimp anzee Research: An Examination of Its Contribution to Biomedical Knowledge and Efficacy in Combating Human Diseases, 47pp. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.releasechimps.org/ pdfs/chimp-efficacy-paper-main.pdf (Accessed 17.08.10).
8. Knight, A. (2007). The poor contribution of chimpanzee experiments to biomedical progress. Journal of Applied Animal Welfare Science 10, 281-308.
9. de Kok, W. (2002). Dutch Lab Chimps to be Retired. Summerville, SC, USA: International Primate Protection League. Available at: http:// www.ippl.org/2002-dutch-chimps.php (Accessed 20.07.10).
10. Vermij, P. (2003). Europe's last research chimps to retire. Nature Medicine 9, 981.
11. NEAVS (2005). End Chimpanzee Research: Over - view - Public Opinion. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.releasechimps.org/ mission/end-chimpanzee-research/ public-opinion (Accessed 18.08.10).
12. US Government Printing Office (2007). Public Law 110-170 - Dec 26. 121 Stat 2465. 110th Con gress (S. 1916), 2pp. Washington, DC, USA: Govern ment Printing Office. Available at: http://frwebgate. access.gpo.gov/cgi-bin/getdoc. cgi?dbname= 110-cong-public-laws&docid=f:publ170.110.pdf (Accessed 18.08.10).
13. OpenCongress (2009). H.R.1326 Great Ape Pro - tection Act. New York, NY, USA: OpenCongress. Available at: http://www.opencongress.org/bill/111-h1326/show (Accessed 18.08.10).
14. Cohen, J. (2007). Biomedical research. The endangered lab chimp. Science, New York 315, 450-452.
15. VandeBerg, J.L. & Zola, S.M. (2005). A unique biomedical resource at risk. Nature, London 437, 30-32.
16. Bailey, J. (2009). An examination of the use of chimpanzees in human cancer research. ATLA 37, 399-416.
17. Bailey, J. (2010). An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. ATLA [In press].
18. Seeff, L.B. (2009). The history of the "natural history" of hepatitis C (1968-2009). Liver International 29, Suppl. 1, 89-99.
19. Feinstone, S.M., Kapikian, A.Z., Purcell, R.H., Alter, H.J. & Holland, P.V. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. New England Journal of Medicine 292, 767-770.
20. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, New York 244, 359-362.
21. Alter, H.J., Purcell, R.H., Shih, J.W., Melpolder, J.C., Houghton, M., Choo, Q.L. & Kuo, G. (1989). Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321, 1494-1500.
22. Kuo, G., Choo, Q.L., Alter, H.J., Gitnick, G.L., Redeker, A.G., Purcell, R.H., Miyamura, T., Dienstag, J.L., Alter, M.J., Stevens, C.E., Tegtmeier, G.E., Bonino, F., Colombo, M., Lee, W-S., Kuo, C., Berger, K., Shuster, J.R., Overby, L.R., Bradley, D.W. & Houghton, M. (1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, New York 244, 362-364.
23. Gottwein, J.M. & Bukh, J. (2008). Cutting the Gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Advances in Virus Research 71, 51-133.
24. Marcellin, P. (2009). Hepatitis B and hepatitis C in 2009. Liver International 29, Suppl. 1, 1-8.
25. Soriano, V., Madejon, A., Vispo, E., Labarga, P., Garcia-Samaniego, J., Martin-Carbonero, L., Sheldon, J., Bottecchia, M., Tuma, P. & Barreiro, P. (2008). Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs 13, 1-19.
26. Shepard, C.W., Finelli, L. & Alter, M.J. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 5, 558-567.
27. Brown, R.S. (2005). Hepatitis C and liver transplantation. Nature, London 436, 973-978.
28. Agnello, V. & De Rosa, F.G. (2004). Extrahepatic disease manifestations of HCV infection: Some current issues. Journal of Hepatology 40, 341-352.
29. Lerat, H., Berby, F., Trabaud, M.A., Vidalin, O., Major, M., Trepo, C. & Inchauspé, G. (1996). Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. Journal of Clinical Investigation 97, 845-851.
30. Barria, M.I., Vera-Otarola, J., Leon, U., Vollrath, V., Marsac, D., Riquelme, A., Lopez-Lastra, M. & Soza, A. (2008). Influence of extrahepatic viral infection on the natural history of hepatitis C. Annals of Hepatology 7, 136-143.
31. Dienstag, J.L. & McHutchison, J.G. (2006). American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130, 231-264; quiz 214-217.
32. Brass, V., Moradpour, D. & Blum, H.E. (2007). Hepatitis C virus infection: In vivo and in vitro models. Journal of Viral Hepatitis 14, Suppl. 1, 64-67.
33. Walters, K-A. & Katze, M.G. (2009). Using high-throughput genomics to study hepatitis C: What determines the outcome of infection? Antiviral Research 81, 198-208.
34. Poynard, T., Bedossa, P. & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349, 825-832.
35. Lauer, G.M. & Walker, B.D. (2001). Hepatitis C virus infection. New England Journal of Medicine 345, 41-52.
36. Albert, M.L., Decalf, J. & Pol, S. (2008). Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C. Journal of Hepatology 49, 1069-1078.
37. Kim, J.W. & Wang, X.W. (2003). Gene expression profiling of preneoplastic liver disease and liver cancer: A new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 24, 363-369.
38. Simmonds, P. (2004). Genetic diversity and evolution of hepatitis C virus - 15 years on. Journal of General Virology 85, 3173-3188.
39. Anon. (2002). National Institutes of Health consensus development conference statement: Management of hepatitis C. Hepatology 36, Suppl. 1, S3-S20.
40. Dhumeaux, D., Marcellin, P. & Lerebours, E. (2003). Treatment of hepatitis C. The 2002 French consensus. Gut 52, 1784-1787.
41. Fried, M.W. & Hadziyannis, S.J. (2004). Treatment of chronic hepatitis C infection with peg-interferons plus ribavirin. Seminars in Liver Disease 24, Suppl. 2, 47-54.
42. Manns, M.P., Foster, G.R., Rockstroh, J.K., Zeuzem, S., Zoulim, F. & Houghton, M. (2007). The way forward in HCV treatment - finding the right path. Nature Reviews Drug Discovery 6, 991-1000.
43. Hadziyannis, S.J., Sette, H.J., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H.J., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A. & Ackrill, A.M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 140, 346-355.
44. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L.J., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J. & Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347, 975-982.
45. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M. & Albrecht, J.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358, 958-965. (Pubitemid 32913521)
46. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S. & Albrecht, J.K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 339, 1485-1492.
47. Muir, A.J., Bornstein, J.D. & Killenberg, P.G. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non- Hispanic whites. New England Journal of Medicine 350, 2265-2271.
48. Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J.P., Degott, C. & Erlinger, S. (1997). Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine 127, 875-881.
49. Maylin, S., Martinot-Peignoux, M., Moucari, R., Boyer, N., Ripault, M.P., Cazals-Hatem, D., Giuily, N., Castelnau, C., Cardoso, A.C., Asselah, T., Feray, C., Nicolas-Chanoine, M.H., Bedossa, P. & Marcellin, P. (2008). Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135, 821-829.
50. Asselah, T., Benhamou, Y. & Marcellin, P. (2009). Protease and polymerase inhibitors for the treatment of hepatitis C. Liver International 29, Suppl. 1, 57-67.
51. Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy, D.G., Okamoto, H., Pawlotsky, J.M., Penin, F., Sablon, E., Shin-I, T., Stuyver, L.J., Thiel, H.J., Viazov, S., Weiner, A.J. & Widell, A. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973.
52. Houghton, M. & Abrignani, S. (2005). Prospects for a vaccine against the hepatitis C virus. Nature, London 436, 961-966.
53. Falck-Ytter, Y., Kale, H., Mullen, K.D., Sarbah, S.A., Sorescu, L. & McCullough, A.J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine 136, 288-292.
54. De Francesco, R. & Migliaccio, G. (2005). Challenges and successes in developing new therapies for hepatitis C. Nature, London 436, 953-960.
55. Feld, J.J. & Hoofnagle, J.H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, London 436, 967-972.
56. Manns, M.P., Wedemeyer, H. & Cornberg, M. (2006). Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 55, 1350-1359.
57. Bowen, D.G. & Walker, C.M. (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, London 436, 946-952.
58. Lang, K. & Weiner, D.B. (2008). Immunotherapy for HCV infection: Next steps. Expert Review of Vaccines 7, 915-923.
59. Bettauer, R.H. (2010). Chimpanzees in hepatitis C virus research: 1998-2007. Journal of Medical Primatology 39, 9-23.
60. Prince, A.M., Brotman, B., Lee, D.H., Pfahler, W., Tricoche, N., Andrus, L. & Shata, M.T. (2005). Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. Journal of Infectious Diseases 192, 1701-1709.
61. Sakai, A., Takikawa, S., Thimme, R., Meunier, J.C., Spangenberg, H.C., Govindarajan, S., Farci, P., Emerson, S.U., Chisari, F.V., Purcell, R.H. & Bukh, J. (2007). In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. Journal of Virology 81, 7208-7219.
62. Yanagi, M., St Claire, M., Shapiro, M., Emerson, S.U., Purcell, R.H. & Bukh, J. (1998). Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244, 161-172.
63. NEAVS (2008). Fearful Knockdowns. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.release chimps.org/lab-life-traumas-g/fearful-knockdowns (Accessed 11.08.10).
64. NEAVS (2009). Hepatitis Detour. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.release chimps.org/harm-suffering/research-current/ hepatitis-detour (Accessed 11.08.10).
65. Bigger, C.B., Brasky, K.M. & Lanford, R.E. (2001). DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. Journal of Virology 75, 7059-7066.
66. Bukh, J., Pietschmann, T., Lohmann, V., Krieger, N., Faulk, K., Engle, R.E., Govindarajan, S., Shapiro, M., St Claire, M. & Bartenschlager, R. (2002). Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the USA 99, 14,416-14,421.
67. Sakai, A., St Claire, M., Faulk, K., Govindarajan, S., Emerson, S.U., Purcell, R.H. & Bukh, J. (2003). The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proceedings of the National Academy of Sciences of the USA 100, 11,646-11,651.
68. Shimizu, Y.K., Igarashi, H., Kiyohara, T., Shapiro, M., Wong, D.C., Purcell, R.H. & Yoshikura, H. (1998). Infection of a chimpanzee with hepatitis C virus grown in cell culture. Journal of General Virology 79, 1383-1386.
69. Su, A.I., Pezacki, J.P., Wodicka, L., Brideau, A.D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R.H., Schultz, P.G. & Chisari, F.V. (2002). Genomic analysis of the host response to hepatitis C virus infection. Proceedings of the National Academy of Sciences of the USA 99, 15,669-15,674.
70. Maillard, P., Krawczynski, K., Nitkiewicz, J., Bronnert, C., Sidorkiewicz, M., Gounon, P., Dubuisson, J., Faure, G., Crainic, R. & Budkowska, A. (2001). Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. Journal of Virology 75, 8240-8250.
71. Caldwell, S.H. (2001). Controlling pain in liver biopsy, or "we will probably need to repeat the biopsy in a year or two to assess the response". American Journal of Gastroenterology 96, 1327-1329.
72. Major, M.E., Mihalik, K., Puig, M., Rehermann, B., Nascimbeni, M., Rice, C.M. & Feinstone, S.M. (2002). Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. Journal of Virology 76, 6586-6595.
73. Yanagi, M., Purcell, R.H., Emerson, S.U. & Bukh, J. (1999). Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262, 250-263.
74. + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. Journal of Virology 77, 4781-4793.
75. Kolykhalov, A.A., Mihalik, K., Feinstone, S.M. & Rice, C.M. (2000). Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. Journal of Virology 74, 2046-2051.
76. Esumi, M., Rikihisa, T., Nishimura, S., Goto, J., Mizuno, K., Zhou, Y.H. & Shikata, T. (1999). Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Archives of Virology 144, 973-980.
77. Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B.B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., Lahm, A., Luzzago, A., Vitelli, A., Colloca, S., Cortese, R. & Nicosia, A. (2006). A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nature Medicine 12, 190-197.
78. Puig, M., Major, M.E., Mihalik, K. & Feinstone, S.M. (2004). Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22, 991-1000.
79. Alter, H.J., Purcell, R.H., Holland, P.V. & Popper, H. (1978). Transmissible agent in non-A, non-B hepatitis. Lancet 312 (8062), 4 March, 459-463.
80. Tabor, E., Gerety, R.J., Drucker, J.A., Seeff, L.B., Hoofnagle, J.H., Jackson, D.R., April, M., Barker, L.F. & Pineda-Tamondong, G. (1978). Trans mission of non-A, non-B hepatitis from man to chimpanzee. Lancet 312 (8062), 4 March, 463-466.
81. He, L.F., Alling, D., Popkin, T., Shapiro, M., Alter, H.J. & Purcell, R.H. (1987). Determining the size of non-A, non-B hepatitis virus by filtration. Journal of Infectious Diseases 156, 636-640.
82. Feinstone, S.M., Mihalik, K.B., Kamimura, T., Alter, H.J., London, W.T. & Purcell, R.H. (1983). Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infection & Immunity 41, 816-821.
83. Farci, P. (2002). Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989; 244:359-362]. Journal of Hepatology 36, 582-585.
84. Kolykhalov, A.A., Agapov, E.V., Blight, K.J., Mihalik, K., Feinstone, S.M. & Rice, C.M. (1997). Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science, New York 277, 570-574.
85. Yanagi, M., Purcell, R.H., Emerson, S.U. & Bukh, J. (1997). Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proceedings of the National Academy of Sciences of the USA 94, 8738-8743.
86. Bukh, J. (2004). A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39, 1469-1475.
87. Lanford, R.E., Bigger, C., Bassett, S. & Klimpel, G. (2001). The chimpanzee model of hepatitis C virus infections. ILAR Journal 42, 117-126.
88. Farci, P., Alter, H.J., Govindarajan, S., Wong, D.C., Engle, R., Lesniewski, R.R., Mushahwar, I.K., Desai, S.M., Miller, R.H., Ogata, N. & Purcell, R.H. (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science, New York 258, 135-140.
89. Prince, A.M., Brotman, B., Huima, T., Pascual, D., Jaffery, M. & Inchauspé, G. (1992). Immunity in hepatitis C infection. Journal of Infectious Diseases 165, 438-443.
90. Bukh, J., Forns, X., Emerson, S.U. & Purcell, R.H. (2001). Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 44, 132-142.
91. Akari, H., Iwasaki, Y., Yoshida, T. & Iijima, S. (2009). Non-human primate surrogate model of hepatitis C virus infection. Microbiology & Immunology 53, 53-57.
92. Inchauspé, G. & Michel, M.L. (2007). Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. Journal of Viral Hepatitis 14, Suppl. 1, 97-103.
93. Nuffield Council on Bioethics (2005). The Ethics of Research Involving Animals, 376pp. London, UK: Nuffield Council on Bioethics. Available at: http://www.nuffieldbioethics.org/fileLibrary/pdf/RIA-Report-FINAL-opt.pdf (Accessed 11.08.10).
94. Carroll, S.S., Ludmerer, S., Handt, L., Koeplinger, K., Zhang, N.R., Graham, D., Davies, M-E., MacCoss, M., Hazuda, D. & Olsen, D.B. (2009). Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrobial Agents & Chemotherapy 53, 926-934.
95. Major, M.E. & Feinstone, S.M. (2000). Characterization of hepatitis C virus infectious clones in chimpanzees: Long-term studies. Current Topics in Microbiology & Immunology 242, 279-298.
96. Bassett, S.E., Brasky, K.M. & Lanford, R.E. (1998). Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. Journal of Virology 72, 2589-2599.
97. Bassett, S.E., Thomas, D.L., Brasky, K.M. & Lanford, R.E. (1999). Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Journal of Virology 73, 1118-1126.
98. Prince, A.M., Brotman, B., Lee, D.H., Ren, L., Moore, B.S. & Scheffel, J.W. (1999). Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. Journal of Infectious Diseases 180, 987-991.
99. Ray, S.C., Mao, Q., Lanford, R.E., Bassett, S., Laeyendecker, O., Wang, Y.M. & Thomas, D.L. (2000). Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. Journal of Virology 74, 3058-3066.
100. Zanetti, A.R., Tanzi, E., Paccagnini, S., Principi, N., Pizzocolo, G., Caccamo, M.L., D'Amico, E., Cambie, G. & Vecchi, L. (1995). Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 345, 289-291.
101. Houghton, M. (2009). Discovery of the hepatitis C virus. Liver International 29, Suppl. 1, 82-88.
102. Alter, H.J. & Houghton, M. (2000). Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nature Medicine 6, 1082-1086.
103. Blumberg, B.S., Alter, H.J. & Visnich, S. (1965). A "new" antigen in leukemia sera. JAMA 191, 541-546.
104. Alter, H.J., Holland, P.V., Morrow, A.G., Purcell, R.H., Feinstone, S.M. & Moritsugu, Y. (1975). Clinical and serological analysis of transfusion-associated hepatitis. Lancet 306 (7940), 8 November, 838-841.
105. Hoofnagle, J.H. & Alter, H.J. (1985). Chronic non- A, non-B hepatitis. Progress in Clinical & Biological Research 182, 63-69.
106. Berman, M., Alter, H.J., Ishak, K.G., Purcell, R.H. & Jones, E.A. (1979). The chronic sequelae of non- A, non-B hepatitis. Annals of Internal Medicine 91, 1-6.
107. Aach, R.D., Szmuness, W., Mosley, J.W., Hollinger, F.B., Kahn, R.A., Stevens, C.E., Edwards, V.M. & Werch, J. (1981). Serum alanine aminotransferase of donors in relation to the risk of non- A,non-B hepatitis in recipients: The transfusion-transmitted viruses study. New England Journal of Medicine 304, 989-994.
108. Alter, M.J., Gerety, R.J., Smallwood, L.A., Sampliner, R.E., Tabor, E., Deinhardt, F., Frosner, G. & Matanoski, G.M. (1982). Sporadic non-A, non- B hepatitis: Frequency and epidemiology in an urban U.S. population. Journal of Infectious Diseases 145, 886-893.
109. Alter, H.J. (1989). Chronic sequences of non-A, non-B hepatitis. In Current Perspectives in Hepatology (ed. L.B. Seeff & J.H. Lewis), pp. 83-97. New York, NY, USA: Plenum Medical.
110. Gilliam, J.H., 3rd, Geisinger, K.R. & Richter, J.E. (1984). Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Annals of Internal Medicine 101, 794-795.
111. Mullis, K.B. & Faloona, F.A. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods in Enzymology 155, 335-350.
112. Colombo, M., Kuo, G., Choo, Q.L., Donato, M.F., Del Ninno, E., Tommasini, M.A., Dioguardi, N. & Houghton, M. (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 334 (8670), 28 October, 1006-1008.
113. Morita, T., Hada, H., Koide, N., Shiraha, H., Shinji, T., Nakamura, M., Ujike, K., Wato, M., Shimomura, H. & Tsuji, T. (1996). Detection of hepatitis C virus RNA in circulating immune complexes by RT-PCR. Hepatogastroenterology 43, 582-585.
114. Fujita, N., Kaito, M., Takeo, M., Iwasa, M., Ikoma, J., Watanabe, S. & Adachi, Y. (2003). Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C. American Journal of Gastroenterology 98, 645-652.
115. Gale, M.J. & Beard, M.R. (2001). Molecular clones of hepatitis C virus: Applications to animal models. ILAR Journal 42, 139-151.
116. Duverlie, G. & Wychowski, C. (2007). Cell culture systems for the hepatitis C virus. World Journal of Gastroenterology 13, 2442-2445.
117. Moormann, R.J., van Gennip, H.G., Miedema, G.K., Hulst, M.M. & van Rijn, P.A. (1996). Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. Journal of Virology 70, 763-770.
118. Bartenschlager, R. (2006). Hepatitis C virus molecular clones: From cDNA to infectious virus particles in cell culture. Current Opinion in Microbiology 9, 416-422.
119. Higashi, Y., Kakumu, S., Yoshioka, K., Wakita, T., Mizokami, M., Ohba, K., Ito, Y., Ishikawa, T., Takayanagi, M. & Nagai, Y. (1993). Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 197, 659-668.
120. Yagi, S., Mori, K., Tanaka, E., Matsumoto, A., Sunaga, F., Kiyosawa, K. & Yamaguchi, K. (2005). Identification of novel HCV subgenome replicating persistently in chronic active hepatitis C patients. Journal of Medical Virology 77, 399-413.
121. Sheehy, P., Mullan, B., Moreau, I., Kenny-Walsh, E., Shanahan, F., Scallan, M. & Fanning, L.J. (2007). In vitro replication models for the hepatitis C virus. Journal of Viral Hepatitis 14, 2-10.
122. Yoo, B.J., Selby, M.J., Choe, J., Suh, B.S., Choi, S.H., Joh, J.S., Nuovo, G.J., Lee, H.S., Houghton, M. & Han, J.H. (1995). Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. Journal of Virology 69, 32-38.
123. Dash, S., Halim, A.B., Tsuji, H., Hiramatsu, N. & Gerber, M.A. (1997). Transfection of HepG2 cells with infectious hepatitis C virus genome. American Journal of Pathology 151, 363-373.
124. Okamoto, H., Okada, S., Sugiyama, Y., Kurai, K., Iizuka, H., Machida, A., Miyakawa, Y. & Mayumi, M. (1991). Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with reported isolates for conserved and divergent regions. Journal of General Virology 72, 2697-2704.
125. Takamizawa, A., Mori, C., Fuke, I., Manabe, S., Murakami, S., Fujita, J., Onishi, E., Andoh, T., Yosh ida, I. & Okayama, H. (1991). Structure and organization of the hepatitis C virus genome isolated from human carriers. Journal of Virology 65, 1105-1113.
126. Kato, N., Hijikata, M., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., Sugimura, T. & Shimotohno, K. (1990). Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proceedings of the National Academy of Sciences of the USA 87, 9524-9528.
127. Bartenschlager, R. & Sparacio, S. (2007). Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Research 127, 195-207.
128. Beard, M.R., Abell, G., Honda, M., Carroll, A., Gartland, M., Clarke, B., Suzuki, K., Lanford, R., Sangar, D.V. & Lemon, S.M. (1999). An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 30, 316-324.
129. Lanford, R.E., Lee, H., Chavez, D., Guerra, B. & Brasky, K.M. (2001). Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. Journal of General Virology 82, 1291-1297.
130. Yanagi, M., St Claire, M., Emerson, S.U., Purcell, R.H. & Bukh, J. (1999). In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proceedings of the National Academy of Sciences of the USA 96, 2291-2295.
131. Myung, J., Khalap, N., Kalkeri, G., Garry, R. & Dash, S. (2001). Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. Journal of Virological Methods 94, 55-67.
132. Lim, S.P., Soo, H.M., Tan, Y.H., Brenner, S., Horstmann, H., MacKenzie, J.M., Ng, M.L., Lim, S.G. & Hong, W. (2002). Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology 303, 79-99.
133. Moradpour, D., Wakita, T., Wands, J.R. & Blum, H.E. (1998). Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochemical & Biophysical Research Communications 246, 920-924. (Pubitemid 28420958)
134. Moradpour, D., Kary, P., Rice, C.M. & Blum, H.E. (1998). Continuous human cell lines inducibly expressing hepatitis C virus structural and non-structural proteins. Hepatology 28, 192-201. (Pubitemid 28300001)
135. Kalkeri, G., Khalap, N., Akhter, S., Garry, R.F., Fermin, C.D. & Dash, S. (2001). Hepatitis C viral proteins affect cell viability and membrane permeability. Experimental & Molecular Pathology 71, 194-208.
136. Huang, Y., Uchiyama, Y., Fujimura, T., Kanamori, H., Doi, T., Takamizawa, A., Hamakubo, T. & Kodama, T. (2001). A human hepatoma cell line expressing hepatitis C virus nonstructural proteins tightly regulated by tetracycline. Biochemical & Biophysical Research Communications 281, 732-740.
137. Qi, Z.T., Kalkeri, G., Hanible, J., Prabhu, R., Bastian, F., Garry, R.F. & Dash, S. (2003). Stem-loop structures II-IV of the 5′ untranslated sequences are required for the expression of the full-length hepatitis C virus genome. Archives of Virology 148, 449-467.
138. Prabhu, R., Joshi, V., Garry, R.F., Bastian, F., Haque, S., Regenstein, F., Thung, S. & Dash, S. (2004). Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Experimental & Molecular Pathology 76, 242-252.
139. Chung, R.T., He, W., Saquib, A., Contreras, A.M., Xavier, R.J., Chawla, A., Wang, T.C. & Schmidt, E.V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proceedings of the National Academy of Sciences of the USA 98, 9847-9852.
140. Harada, T., Kim, D.W., Sagawa, K., Suzuki, T., Takahashi, K., Saito, I., Matsuura, Y. & Miyamura, T. (1995). Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. Journal of General Virology 76, 1215-1221.
141. Heim, M.H., Moradpour, D. & Blum, H.E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Journal of Virology 73, 8469-8475.
142. Schmidt-Mende, J., Bieck, E., Hugle, T., Penin, F., Rice, C.M., Blum, H.E. & Moradpour, D. (2001). Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. Journal of Biological Chemistry 276, 44,052-44,063.
143. Wolk, B., Sansonno, D., Krausslich, H.G., Dammacco, F., Rice, C.M., Blum, H.E. & Moradpour, D. (2000). Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. Journal of Virology 74, 2293-2304.
144. Cooper, S., Erickson, A.L., Adams, E.J., Kansopon, J., Weiner, A.J., Chien, D.Y., Houghton, M., Parham, P. & Walker, C.M. (1999). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439-449.
145. Koziel, M.J., Dudley, D., Afdhal, N., Choo, Q.L., Houghton, M., Ralston, R. & Walker, B.D. (1993). Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. Journal of Virology 67, 7522-7532.
146. Bronowicki, J.P., Vetter, D., Uhl, G., Hudziak, H., Uhrlacher, A., Vetter, J.M. & Doffoel, M. (1997). Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. Journal of Infectious Diseases 176, 518-522.
147. + T cells in hepatitis C virus-exposed healthy seronegative donors. Journal of Immunology 162, 6681-6689.
148. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J.L., Manns, M.P. & Rehermann, B. (2000). Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Medicine 6, 578-582.
149. Barrett, S., Ryan, E. & Crowe, J. (1999). Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Journal of Hepatology 30, 979-983.
150. Chisari, F.V. (1997). Cytotoxic T cells and viral hepatitis. Journal of Clinical Investigation 99, 1472-1477.
151. Gruner, N.H., Gerlach, T.J., Jung, M.C., Diepolder, H.M., Schirren, C.A., Schraut, W.W., Hoffmann, R., Zachoval, R., Santantonio, T., Cucchiarini, M., Cerny, A. & Pape, G.R. (2000). Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. Journal of Infectious Diseases 181, 1528-1536.
152. Cerny, A. & Chisari, F.V. (1999). Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology 30, 595-601.
153. + T lymphocytes in acute and chronic hepatitis C. Journal of Molecular Medicine 74, 583-588.
154. Lechner, F., Wong, D.K., Dunbar, P.R., Chapman, R., Chung, R.T., Dohrenwend, P., Robbins, G., Phillips, R., Klenerman, P. & Walker, B.D. (2000). Analysis of successful immune responses in persons infected with hepatitis C virus. Journal of Experimental Medicine 191, 1499-1512.
155. Thimme, R., Oldach, D., Chang, K.M., Steiger, C., Ray, S.C. & Chisari, F.V. (2001). Determinants of viral clearance and persistence during acute hepatitis C virus infection. Journal of Experimental Medicine 194, 1395-1406.
156. + T cells in chronic hepatitis C virus infection. Journal of Immunology 169, 3447-3458.
157. Bukh, J., Thimme, R., Meunier, J-C., Faulk, K., Spangenberg, H.C., Chang, K-M., Satterfield, W., Chisari, F.V. & Purcell, R.H. (2008). Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. Journal of Virology 82, 8183-8195.
158. Lanford, R.E. & Bigger, C. (2002). Advances in model systems for hepatitis C virus research. Virology 293, 1-9.
159. Bassett, S.E., Guerra, B., Brasky, K., Miskovsky, E., Houghton, M., Klimpel, G.R. & Lanford, R.E. (2001). Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33, 1479-1487.
160. Lanford, R.E., Guerra, B., Chavez, D., Bigger, C., Brasky, K.M., Wang, X.H., Ray, S.C. & Thomas, D.L. (2004). Cross-genotype immunity to hepatitis C virus. Journal of Virology 78, 1575-1581.
161. Kaplan, D.E., Sugimoto, K., Newton, K., Valiga, M.E., Ikeda, F., Aytaman, A., Nunes, F.A., Lucey, M.R., Vance, B.A., Vonderheide, R.H., Reddy, K.R., McKeating, J.A. & Chang, K.M. (2007). Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132, 654-666.
162. von Hahn, T., Yoon, J.C., Alter, H., Rice, C.M., Rehermann, B., Balfe, P. & McKeating, J.A. (2007). Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678.
163. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. & Perelson, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, New York 282, 103-107.
164. Lam, N.P., Neumann, A.U., Gretch, D.R., Wiley, T.E., Perelson, A.S. & Layden, T.J. (1997). Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26, 226-231.
165. Bigger, C.B., Guerra, B., Brasky, K.M., Hubbard, G., Beard, M.R., Luxon, B.A., Lemon, S.M. & Lanford, R.E. (2004). Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. Journal of Virology 78, 13,779-13,792.
166. Lanford, R.E., Guerra, B., Lee, H., Chavez, D., Brasky, K.M. & Bigger, C.B. (2006). Genomic response to interferon-alpha in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics. Hepatology 43, 961-972.
167. Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C. & Manns, M.P. (2001). Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine 345, 1452-1457.
168. Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D., Dhumeaux, D., Maurel, P. & Pawlotsky, J.M. (2002). Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. Journal of Virology 76, 8189-8199.
169. Shimizu, Y.K. & Yoshikura, H. (1994). Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. Journal of Virology 68, 8406-8408.
170. Frese, M., Pietschmann, T., Moradpour, D., Haller, O. & Bartenschlager, R. (2001). Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology 82, 723-733.
171. Guo, J.T., Bichko, V.V. & Seeger, C. (2001). Effect of alpha interferon on the hepatitis C virus replicon. Journal of Virology 75, 8516-8523.
172. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L. & Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, New York 285, 110-113.
173. Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L. & Bigger, C. (2003). Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. Journal of Virology 77, 1092-1104.
174. Blight, K.J., Kolykhalov, A.A. & Rice, C.M. (2000). Efficient initiation of HCV RNA replication in cell culture. Science, New York 290, 1972-1974.
175. Helbig, K.J., Lau, D.T., Semendric, L., Harley, H.A. & Beard, M.R. (2005). Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42, 702-710.
176. Smith, M.W., Yue, Z.N., Korth, M.J., Do, H.A., Boix, L., Fausto, N., Bruix, J., Carithers, R.L.J. & Katze, M.G. (2003). Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology 38, 1458-1467.
177. Ji, X., Cheung, R., Cooper, S., Li, Q., Greenberg, H.B. & He, X.S. (2003). Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37, 610-621.
178. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.L., Coltescu, C., Heathcote, J., Edwards, A.M. & McGilvray, I.D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444.
179. MacQuillan, G.C., Mamotte, C., Reed, W.D., Jeffrey, G.P. & Allan, J.E. (2003). Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. Journal of Medical Virology 70, 219-227.
180. Huang, Y., Feld, J.J., Sapp, R.K., Nanda, S., Lin, J.H., Blatt, L.M., Fried, M.W., Murthy, K. & Liang, T.J. (2007). Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132, 733-744.
181. Der, S.D., Zhou, A., Williams, B.R. & Silverman, R.H. (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of Sciences of the USA 95, 15,623-15,628.
182. Tan, H., Derrick, J., Hong, J., Sanda, C., Grosse, W.M., Edenberg, H.J., Taylor, M., Seiwert, S. & Blatt, L.M. (2005). Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. Journal of Interferon & Cytokine Research 25, 632-649.
183. Meyer, M.F., Lehmann, M., Cornberg, M., Wieg, J., Manns, M.P., Klade, C. & Wedemeyer, H. (2007). Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virology Journal 4, 58.
184. Hassan, M., Selimovic, D., Ghozlan, H. & Abdelkader, O. (2009). Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 49, 1469-1482.
185. Pfeffer, S. & Baumert, T.F. (2009). Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. Journal of Hepatology 51, 606-609.
186. Smith, M.W., Walters, K.A., Korth, M.J., Fitzgibbon, M., Proll, S., Thompson, J.C., Yeh, M.M., Shuhart, M.C., Furlong, J.C., Cox, P.P., Thomas, D.L., Phillips, J.D., Kushner, J.P., Fausto, N., Carithers, R.L.J. & Katze, M.G. (2006). Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 130, 179-187.
187. Lau, D.T., Luxon, B.A., Xiao, S.Y., Beard, M.R. & Lemon, S.M. (2005). Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology 42, 273-281.
188. Ryder, S.D., Irving, W.L., Jones, D.A., Neal, K.R. & Underwood, J.C. (2004). Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 53, 451-455.
189. Hui, C.K., Belaye, T., Montegrande, K. & Wright, T.L. (2003). A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. Journal of Hepatology 38, 511-517.
190. Boccato, S., Pistis, R., Noventa, F., Guido, M., Benvegnu, L. & Alberti, A. (2006). Fibrosis progression in initially mild chronic hepatitis C. Journal of Viral Hepatitis 13, 297-302.
191. Ghany, M.G., Kleiner, D.E., Alter, H., Doo, E., Khokar, F., Promrat, K., Herion, D., Park, Y., Liang, T.J. & Hoofnagle, J.H. (2003). Progression of fibrosis in chronic hepatitis C. Gastroenterology 124, 97-104.
192. Levine, R.A., Sanderson, S.O., Ploutz-Snyder, R., Murray, F., Kay, E., Hegarty, J., Nolan, N., Kelleher, D., McDonald, G., O'Keane, J.C. & Crowe, J. (2006). Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clinical Gastroenterology & Hepatology 4, 1271-1277.
193. Persico, M., Persico, E., Suozzo, R., Conte, S., De Seta, M., Coppola, L., Palmentieri, B., Sasso, F.C. & Torella, R. (2000). Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118, 760-764.
194. Martinot-Peignoux, M., Boyer, N., Cazals-Hatem, D., Pham, B.N., Gervais, A., Le Breton, V., Levy, S., Degott, C., Valla, D.C. & Marcellin, P. (2001). Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34, 1000-1005.
195. Stevenson, F.K. & Rosenberg, W. (2001). DNA vaccination: A potential weapon against infection and cancer. Vox Sanguinis 80, 12-18.
196. Elmowalid, G.A., Qiao, M., Jeong, S-H., Borg, B.B., Baumert, T.F., Sapp, R.K., Hu, Z., Murthy, K. & Liang, T.J. (2007). Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proceedings of the National Academy of Sciences of the USA 104, 8427-8432.
197. Stoll-Keller, F., Barth, H., Fafi-Kremer, S., Zeisel, M.B. & Baumert, T.F. (2009). Development of hepatitis C virus vaccines: Challenges and progress. Expert Review of Vaccines 8, 333-345.
198. de Bruijne, J., Weegink, C.J., Jansen, P.L.M. & Reesink, H.W. (2009). New developments in the antiviral treatment of hepatitis C. Vox Sanguinis 97, 1-12.
199. Choo, Q.L., Kuo, G., Ralston, R., Weiner, A., Chien, D., Van Nest, G., Han, J., Berger, K., Thudium, K., Kuo, C., Kansopon, J., McFarland, J., Tabrizi, A., Ching, K., Moss, B., Cummins, L.B., Houghton, M. & Muchmore, E. (1994). Vaccination of chimpanzees against infection by the hepatitis C virus. Proceedings of the National Academy of Sciences of the USA 91, 1294-1298.
200. Rollier, C., Depla, E., Drexhage, J.A., Verschoor, E.J., Verstrepen, B.E., Fatmi, A., Brinster, C., Fournillier, A., Whelan, J.A., Whelan, M., Jacobs, D., Maertens, G., Inchauspé, G. & Heeney, J.L. (2004). Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. Journal of Virology 78, 187-196.
201. Jeong, S.H., Qiao, M., Nascimbeni, M., Hu, Z., Rehermann, B., Murthy, K. & Liang, T.J. (2004). Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. Journal of Virology 78, 6995-7003.
202. Abraham, J.D., Himoudi, N., Kien, F., Berland, J.L., Codran, A., Bartosch, B., Baumert, T., Paranhos- Baccala, G., Schuster, C., Inchauspé, G. & Kieny, M.P. (2004). Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 22, 3917-3928.
203. Brinster, C., Chen, M., Boucreux, D., Paranhos-Baccala, G., Liljestrom, P., Lemmonier, F. & Inchauspé, G. (2002). Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. Journal of General Virology 83, 369-381.
204. O'Hagan, D.T., Singh, M., Dong, C., Ugozzoli, M., Berger, K., Glazer, E., Selby, M., Wininger, M., Ng, P., Crawford, K., Paliard, X., Coates, S. & Houghton, M. (2004). Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23, 672-680.
205. Wuest, T., Both, G.W., Prince, A.M., Hofmann, C. & Loser, P. (2004). Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 22, 2717-2721.
206. Perri, S., Greer, C.E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R.E., Tang, Z., Bin, Q., Dubensky, T.W.J., Vajdy, M., Otten, G.R. & Polo, J.M. (2003). An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. Journal of Virology 77, 10,394-10,403.
207. Pancholi, P., Perkus, M., Tricoche, N., Liu, Q. & Prince, A.M. (2003). DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCVvaccinia virus infection in HLA-A2.1-transgenic mice. Journal of Virology 77, 382-390.
208. Youn, J.W., Hu, Y.W., Tricoche, N., Pfahler, W., Shata, M.T., Dreux, M., Cosset, F.L., Folgori, A., Lee, D.H., Brotman, B. & Prince, A.M. (2008). Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. Journal of Virology 82, 10,896-10,905.
209. Ma, X., Forns, X., Gutierrez, R., Mushahwar, I.K., Wu, T., Payette, P.J., Bukh, J., Purcell, R.H. & Davis, H.L. (2002). DNA-based vaccination against hepatitis C virus (HCV): Effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20, 3263-3271.
210. Song, M.K., Lee, S.W., Suh, Y.S., Lee, K.J. & Sung, Y.C. (2000). Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. Journal of Virology 74, 2920-2925.
211. Matsui, M., Moriya, O. & Akatsuka, T. (2003). Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 21, 1629-1639.
212. Makimura, M., Miyake, S., Akino, N., Takamori, K., Matsuura, Y., Miyamura, T. & Saito, I. (1996). Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 14, 28-36.
213. Engler, O.B., Schwendener, R.A., Dai, W.J., Wolk, B., Pichler, W., Moradpour, D., Brunner, T. & Cerny, A. (2004). A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23, 58-68.
214. Gehring, S., Gregory, S.H., Kuzushita, N. & Wands, J.R. (2005). Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. Journal of Medical Virology 75, 249-257.
215. Gordon, E.J., Bhat, R., Liu, Q., Wang, Y.F., Tackney, C. & Prince, A.M. (2000). Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. Journal of Infectious Diseases 181, 42-50.
216. Inchauspé, G., Major, M.E., Nakano, I., Vitvitski, L. & Trepo, C. (1997). DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15, 853-856.
217. Inchauspé, G., Major, M.E., Nakano, I., Vivitski, L., Maisonnas, M. & Trepo, C. (1998). Immune responses against hepatitis C virus structural proteins following genetic immunisation. Developments in Biological Standardization 92, 163-168.
218. Major, M.E., Vitvitski, L., Mink, M.A., Schleef, M., Whalen, R.G., Trepo, C. & Inchauspé, G. (1995). DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. Journal of Virology 69, 5798-5805.
219. Youn, J.W., Park, S.H., Cho, J.H. & Sung, Y.C. (2003). Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. Journal of Virology 77, 11,596-11,602.
220. Zhu, L.X., Liu, J., Ye, Y., Xie, Y.H., Kong, Y.Y., Li, G.D. & Wang, Y. (2004). A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World Journal of Gastroenterology 10, 2488-2492.
221. Yu, H., Babiuk, L.A. & van Drunen Littel-van den Hurk, S. (2004). Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. Journal of General Virology 85, 1533-1543.
222. Pancholi, P., Liu, Q., Tricoche, N., Zhang, P., Perkus, M.E. & Prince, A.M. (2000). DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. Journal of Infectious Diseases 182, 18-27.
223. Park, S.H., Yang, S.H., Lee, C.G., Youn, J.W., Chang, J. & Sung, Y.C. (2003). Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21, 4555-4564.
224. Netter, H.J., Macnaughton, T.B., Woo, W.P., Tindle, R. & Gowans, E.J. (2001). Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. Journal of Virology 75, 2130-2141.
225. Lee, S.W., Cho, J.H., Lee, K.J. & Sung, Y.C. (1998). Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Molecules & Cells 8, 444-451.
226. Lee, S.W., Cho, J.H. & Sung, Y.C. (1998). Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. Journal of Virology 72, 8430-8436.
227. Rollier, C.S., Paranhos-Baccala, G., Verschoor, E.J., Verstrepen, B.E., Drexhage, J.A., Fagrouch, Z., Berland, J.L., Komurian-Pradel, F., Duverger, B., Himoudi, N., Staib, C., Meyr, M., Whelan, M., Whelan, J.A., Adams, V.C., Larrea, E., Riezu, J.I., Lasarte, J.J., Bartosch, B., Cosset, F.L., Spaan, W.J., Diepolder, H.M., Pape, G.R., Sutter, G., Inchauspé, G. & Heeney, J.L. (2007). Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45, 602-613.
228. Youn, J.W., Park, S.H., Lavillette, D., Cosset, F.L., Yang, S.H., Lee, C.G., Jin, H.T., Kim, C.M., Shata, M.T., Lee, D.H., Pfahler, W., Prince, A.M. & Sung, Y.C. (2005). Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42, 1429-1436.
229. Polakos, N.K., Drane, D., Cox, J., Ng, P., Selby, M.J., Chien, D., O'Hagan, D.T., Houghton, M. & Paliard, X. (2001). Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. Journal of Immunology 166, 3589-3598.
230. Franzusoff, A., Duke, R.C., King, T.H., Lu, Y. & Rodell, T.C. (2005). Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opinion on Biological Therapy 5, 565-575.
231. Leroux-Roels, G., Depla, E., Hulstaert, F., Tob-back, L., Dincq, S., Desmet, J., Desombere, I. & Maertens, G. (2004). A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers. Vaccine 22, 3080-3086.
232. Nevens, F., Roskams, T., Van Vlierberghe, H., Horsmans, Y., Sprengers, D., Elewaut, A., Desmet, V., Leroux-Roels, G., Quinaux, E., Depla, E., Dincq, S., Vander Stichele, C., Maertens, G. & Hulstaert, F. (2003). A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38, 1289-1296.
233. Firbas, C., Jilma, B., Tauber, E., Buerger, V., Jelovcan, S., Lingnau, K., Buschle, M., Frisch, J. & Klade, C.S. (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24, 4343-4353.
234. Klade, C.S., Wedemeyer, H., Berg, T., Hinrichsen, H., Cholewinska, G., Zeuzem, S., Blum, H., Buschle, M., Jelovcan, S., Buerger, V., Tauber, E., Frisch, J. & Manns, M.P. (2008). Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134, 1385-1395.
235. Schlaphoff, V., Klade, C.S., Jilma, B., Jelovcan, S.B., Cornberg, M., Tauber, E., Manns, M.P. & Wedemeyer, H. (2007). Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25, 6793-6806.
236. Yutani, S., Yamada, A., Yoshida, K., Takao, Y., Tamura, M., Komatsu, N., Ide, T., Tanaka, M., Sata, M. & Itoh, K. (2007). Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25, 7429-7435.
237. Sakamoto, N. & Watanabe, M. (2009). New therapeutic approaches to hepatitis C virus. Journal of Gastroenterology 44, 643-649.
238. Foy, E., Li, K., Sumpter, R.J., Loo, Y.M., Johnson, C.L., Wang, C., Fish, P.M., Yoneyama, M., Fujita, T., Lemon, S.M. & Gale, M.J. (2005). Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proceedings of the National Academy of Sciences of the USA 102, 2986-2991.
239. Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., Ray, S.C., Gale, M.J. & Lemon, S.M. (2005). Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proceedings of the National Academy of Sciences of the USA 102, 2992-2997.
240. Lamarre, D., Anderson, P.C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bos, M., Cameron, D.R., Cartier, M., Cordingley, M.G., Faucher, A.M., Goudreau, N., Kawai, S.H., Kukolj, G., Lagace, L., LaPlante, S.R., Narjes, H., Poupart, M.A., Rancourt, J., Sentjens, R.E., St George, R., Simoneau, B., Steinmann, G., Thibeault, D., Tsantrizos, Y.S., Weldon, S.M., Yong, C.L. & Llinas-Brunet, M. (2003). An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, London 426, 186-189.
241. Crotta, S., Stilla, A., Wack, A., D'Andrea, A., Nuti, S., D'Oro, U., Mosca, M., Filliponi, F., Brunetto, R.M., Bonino, F., Abrignani, S. & Valiante, N.M. (2002). Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. Journal of Experimental Medicine 195, 35-41.
242. Tseng, C.T. & Klimpel, G.R. (2002). Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. Journal of Experimental Medicine 195, 43-49.
243. Forns, X., Bukh, J. & Purcell, R.H. (2002). The challenge of developing a vaccine against hepatitis C virus. Journal of Hepatology 37, 684-695.
244. Pestka, J.M., Zeisel, M.B., Blaser, E., Schurmann, P., Bartosch, B., Cosset, F.L., Patel, A.H., Meisel, H., Baumert, J., Viazov, S., Rispeter, K., Blum, H.E., Roggendorf, M. & Baumert, T.F. (2007). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proceedings of the National Academy of Sciences of the USA 104, 6025-6030.
245. Lavillette, D., Morice, Y., Germanidis, G., Donot, P., Soulier, A., Pagkalos, E., Sakellariou, G., Intrator, L., Bartosch, B., Pawlotsky, J.M. & Cosset, F.L. (2005). Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. Journal of Virology 79, 6023-6034.
246. Haberstroh, A., Schnober, E.K., Zeisel, M.B., Carolla, P., Barth, H., Blum, H.E., Cosset, F.L., Koutsoudakis, G., Bartenschlager, R., Union, A., Depla, E., Owsianka, A., Patel, A.H., Schuster, C., Stoll-Keller, F., Doffoel, M., Dreux, M. & Baumert, T.F. (2008). Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135, 1719-1728.e1.
247. De Francesco, R., Neddermann, P., Tomei, L., Steinkuhler, C., Gallinari, P. & Folgori, A. (2000). Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: Implications for development of antiviral agents and vaccines. Seminars in Liver Disease 20, 69-83.
248. Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A. & Rice, C.M. (2005). Complete replication of hepatitis C virus in cell culture. Science, New York 309, 623-626.
249. HCV Advocate (2009). Hepatitis C Treatments in Current Clinical Development (ed. A. Franciscus), 21pp. San Francisco, CA, USA: HCV Advocate. Available at: http://www.hcvadvocate.org/hepatitis/ hepC/HCVDrugs.html (Accessed 17.08.10).
250. Davis, G.L., Nelson, D.R., Terrault, N., Pruett, T.L., Schiano, T.D., Fletcher, C.V., Sapan, C.V., Riser, L.N., Li, Y., Whitley, R.J. & Gnann, J.W.J. (2005). A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transplantation 11, 941-949.
251. Schiano, T.D., Charlton, M., Younossi, Z., Galun, E., Pruett, T., Tur-Kaspa, R., Eren, R., Dagan, S., Graham, N., Williams, P.V. & Andrews, J. (2006). Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transplantation 12, 1381-1389.
252. Yu, M.Y., Bartosch, B., Zhang, P., Guo, Z.P., Renzi, P.M., Shen, L.M., Granier, C., Feinstone, S.M., Cosset, F.L. & Purcell, R.H. (2004). Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proceedings of the National Academy of Sciences of the USA 101, 7705-7710.
253. Krawczynski, K., Alter, M.J., Tankersley, D.L., Beach, M., Robertson, B.H., Lambert, S., Kuo, G., Spelbring, J.E., Meeks, E., Sinha, S. & Carson, D.A. (1996). Effect of immune globulin on the prevention of experimental hepatitis C virus infection. Journal of Infectious Diseases 173, 822-828.
254. Soler, M., McHutchison, J.G., Kwoh, T.J., Dorr, F.A. & Pawlotsky, J.M. (2004). Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antiviral Therapy 9, 953-968.
255. Usman, N. & Blatt, L.M. (2000). Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics. Journal of Clinical Investigation 106, 1197-1202.
256. ClinicalTrials.gov (2009). Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/ NCT00255177?te rm=VGX&rank=4 (Accessed 17.08.10).
257. ClinicalTrials.gov (2008). A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT00332176? term=celgosivir&rank=1 (Accessed 17.08.10).
258. Del Vecchio, A.M. & Sarisky, R.T. (2006). Small molecule and biologic inhibitors of hepatitis C virus: A symbiotic approach. Mini Reviews in Medicinal Chemistry 6, 1263-1268.
259. Mo, H., Lu, L., Pilot-Matias, T., Pithawalla, R., Mondal, R., Masse, S., Dekhtyar, T., Ng, T., Koev, G., Stoll, V., Stewart, K.D., Pratt, J., Donner, P., Rockway, T., Maring, C. & Molla, A. (2005). Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrobial Agents & Chemotherapy 49, 4305-4314.
260. Lu, L., Dekhtyar, T., Masse, S., Pithawalla, R., Krishnan, P., He, W., Ng, T., Koev, G., Stewart, K., Larson, D., Bosse, T., Wagner, R., Pilot-Matias, T., Mo, H. & Molla, A. (2007). Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Research 76, 93-97.
261. Chen, C.M., He, Y., Lu, L., Lim, H.B., Tripathi, R.L., Middleton, T., Hernandez, L.E., Beno, D.W., Long, M.A., Kati, W.M., Bosse, T.D., Larson, D.P., Wagner, R., Lanford, R.E., Kohlbrenner, W.E., Kempf, D.J., Pilot-Matias, T.J. & Molla, A. (2007). Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrobial Agents & Chemotherapy 51, 4290-4296.
262. Kronenberger, B. & Zeuzem, S. (2008). Future treatment options for HCV: Double, triple, what is the optimal combination? Best Practice & Research Clinical Gastroenterology 22, 1123-1136.
263. Coelmont, L., Paeshuyse, J., Windisch, M.P., De Clercq, E., Bartenschlager, R. & Neyts, J. (2006). Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrobial Agents & Chemotherapy 50, 3444-3446.
264. Soriano, V., Peters, M.G. & Zeuzem, S. (2009). New therapies for hepatitis C virus infection. Clinical Infectious Diseases 48, 313-320.
265. Yao, N., Hesson, T., Cable, M., Hong, Z., Kwong, A.D., Le, H.V. & Weber, P.C. (1997). Structure of the hepatitis C virus RNA helicase domain. Nature Structural Biology 4, 463-467.
266. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O'Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R. & Thomson, J.A. (1996). Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355.
267. Lin, C., Kwong, A.D. & Perni, R.B. (2006). Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infectious Disorders Drug Targets 6, 3-16.
268. Lin, K., Perni, R.B., Kwong, A.D. & Lin, C. (2006). VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrobial Agents & Chemotherapy 50, 1813-1822.
269. Malcolm, B.A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., Ingravallo, P., Jiang, C., Kong, R., Lu, J., Pichardo, J., Prongay, A., Skelton, A., Tong, X., Venkatraman, S., Xia, E., Girijavallabhan, V. & Njoroge, F.G. (2006). SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrobial Agents & Chemo - therapy 50, 1013-1020.
270. Neukam, K., Macías, J., Mira, J.A. & Pineda, J.A. (2009). A review of current anti-HCV treatment regimens and possible future strategies. Expert Opinion on Pharmacotherapy 10, 417-433.
271. Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A. & Kwong, A.D. (2004). In vitro resist ance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. Journal of Biological Chemistry 279, 17,508-17,514.
272. Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R.E., Calleja, J.L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R.L., Yong, C.L., Nehmiz, G. & Steinmann, G.G. (2004). Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355.
273. Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y. & Shimotohno, K. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Molecular Cell 19, 111-122.
274. Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., Nicolas-Metral, V., Dumont, J.M., Porchet, H., Crabbe, R. & Scalfaro, P. (2008). The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817-826.
275. Crabbé, R., Vuagniaux, G., Dumont, J-M., Nicolas-Métral,
276. Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J.M., Scalfaro, P., Bartenschlager, R. & Neyts, J. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761-770.
277. Rossignol, J.F., Elfert, A., El-Gohary, Y. & Keeffe, E.B. (2009). Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856-862.
278. De Leede, L.G., Humphries, J.E., Bechet, A.C., Van Hoogdalem, E.J., Verrijk, R. & Spencer, D.G. (2008). Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. Journal of Interferon & Cytokine Research 28, 113-122.
279. Rustgi, V.K. (2009). Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Current Medical Research & Opinion 25, 991-1002.
280. Horsmans, Y., Berg, T., Desager, J.P., Mueller, T., Schott, E., Fletcher, S.P., Steffy, K.R., Bauman, L.A., Kerr, B.M. & Averett, D.R. (2005). Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42, 724-731.
281. McHutchison, J.G., Bacon, B.R., Gordon, S.C., Lawitz, E., Shiffman, M., Afdhal, N.H., Jacobson, I.M., Muir, A., Al-Adhami, M., Morris, M.L., Lekstrom-Himes, J.A., Efler, S.M. & Davis, H.L. (2007). Phase 1B, randomized, double-blind, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46, 1341-1349.
282. Gish, R.G., Arora, S., Rajender Reddy, K., Nelson, D.R., O'Brien, C., Xu, Y. & Murphy, B. (2007). Virological response and safety outcomes in therapy- naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology 47, 51-59.
283. Hirata, Y., Sudoh, M. & Kohara, M. (2008). Suppression of hepatitis C virus with the reagent targetting host factors. [In Japanese] Uirusu 58, 207-213.
284. Krawczyk, M., Wasowska-Lukawska, M., Oszczapowicz, I. & Boguszewska-Chachulska, A.M. (2009). Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds. Biological Chemistry 390, 351-360.
285. Pawlotsky, J.M. & McHutchison, J.G. (2004). Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference. Hepatology 39, 554-567.
286. Standring, D.N., Lanford, R., Wright, T., Chung, R.T., Bichko, V., Cretton-Scott, E., Pan-Zhou, X., Bergelson, S., Qu, L., Tausek, M., Bridges, E., Moussa, A., Storer, R., Pierra, C., Benzaria, S., Gosselin, G., La Colla, P. & Sommadossi, J.P. (2003). NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. Journal of Hepatology 38, 3-64.
287. HCV Advocate (2007). Newsletter May 2007, 10pp. San Francisco, CA, USA: HCV Advocate. Available at: http://www.hcvadvocate.org/news/newsLetter/ 2007/advocate0507.html (Accessed 17.08.10).
288. Pockros, P.J. (2009). New Frontiers in Therapy Clinical Symposium: New Direct Acting Antivirals (DAAs) in Development for HCV Infection. Bethesda, MD, USA: Digestive Disease Week. Available at: http://www.ddw.org/user-assets/ documents/PDF/01-program/2009/Handouts3/Sp508%20Paul%20Pockros.pdf (Accessed 17.08.10).
289. Standring, D.N., Lanford, R., Li, B., Panzo, R.J., Seifer, M., Larsson, M., Good, S.S. & Zhou, X.J. (2009). Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/ 2009/EASL/EASL-63.htm (Accessed 17.08.10).
290. Olsen, D.B., Carroll, S.S., Handt, L., Ludmerer, S., Graham, D., Fandozzi, C., DeLuca, L., Liverton, N., Vacca, J. & Hazuda, D. (2009). HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2007/EASL/EASL-59.htm (Accessed 17.08.10).
291. Olsen, D.B., Carroll, S.S., Handt, L., Ludmerer, S., Graham, D., Fandozzi, C., DeLuca, L., Liverton, N., Vacca, J. & Hazuda, D. (2009). Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2007/EASL/EASL-14.htm (Accessed 17.08.10).
292. Anon. (2009). The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees. New York, NY, USA: National AIDS Treatment Advocacy Project. Avail able at: http://www.natap.org/2006/ICAAC/ICAAC-13.htm (Accessed 17.08.10).
293. Southwest Foundation for Biomedical Research (2009). New drug technology produces marked improvement in hepatitis C therapy in animals; may be useful for a wide range of diseases. San Antonio, TX, USA: Southwest Foundation for Biomedical Research. Available at: http://www.sfbr.org/News/detail.aspx?id=167 (Accessed 17.08.10).
294. Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., Kauppinen, S. & Orum, H. (2009). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, New York 327, 198-201.
295. Ryder, N.S. (2007). Discontinued drugs in 2006: Anti-infectives. Expert Opinion on Investigational Drugs 16, 1867-1878.
296. Ryder, N.S. (2009). Discontinued drugs in 2007: Anti-infectives. Expert Opinion on Investigational Drugs 18, 1-11.
297. Ryder, N.S. (2010). Discontinued drugs in 2008: Anti-infectives. Expert Opinion on Investigational Drugs 19, 1-21.
298. Brown-Augsburger, P., Yue, X.M., Lockridge, J.A., McSwiggen, J.A., Kamboj, D. & Hillgren, K.M. (2004). Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. Journal of Pharmaceutical & Biomedical Analysis 34, 129-139.
299. Gonzalez-Aseguinolaza, G., Crettaz, J., Ochoa, L., Otano, I., Aldabe, R. & Paneda, A. (2006). Gene therapy for viral hepatitis. Expert Opinion on Biological Therapy 6, 1263-1278.
300. SureChem (undated). Compounds and pharmaceutical compositions for the treatment of viral infections: Publication Number: 20080286230. Example 43: Demonstration of Potent Antiviral Activity of Second Generation Nucleoside Inhibitors, B102, in HCV-Infected Chimpanzees. London, UK : SureChem. Available at: http://www. surechem.org/index.php?Action=document&docId =1953837&db=USPTOA&tab=desc&lang=&db-query= 0%3A%3A0%3A%3A0%3A&markupType= all (Accessed 17.08.10).
301. Meuleman, P. & Leroux-Roels, G. (2008). The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Research 80, 231-238.
302. Mercer, D.F., Schiller, D.E., Elliott, J.F., Douglas, D.N., Hao, C., Rinfret, A., Addison, W.R., Fischer, K.P., Churchill, T.A., Lakey, J.R., Tyrrell, D.L. & Kneteman, N.M. (2001). Hepatitis C virus replication in mice with chimeric human livers. Nature Medicine 7, 927-933.
303. Meuleman, P., Libbrecht, L., De Vos, R., de Hemptinne, B., Gevaert, K., Vandekerckhove, J., Roskams, T. & Leroux-Roels, G. (2005). Morphol - ogical and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41, 847-856.
304. Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M. & Sarnow, P. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science, New York 309, 1577-1581.
305. Jopling, C.L., Norman, K.L. & Sarnow, P. (2006). Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harbor Symposia on Quantitative Biology 71, 369-376.
306. ClinicalTrials.gov (2009). Safety Study of SPC3649 in Healthy Men. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials. gov/ct2/show/NCT00688012?term=SPC3649&r ank=2 (Accessed 17.08.10).
307. ClinicalTrials.gov (2010). SPC3649 Multiple Dose Study in Healthy Volunteers. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT00979927?te rm=SPC3649&rank=1 (Accessed 17.08.10).
308. Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H.F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E.M. & Kauppinen, S. (2008). LNA-mediated microRNA silencing in non-human primates. Nature, London 452, 896-899.
309. Elmen, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjarn, M., Hansen, J.B., Hansen, H.F., Straarup, E.M., McCullagh, K., Kearney, P. & Kauppinen, S. (2008). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Research 36, 1153-1162.
310. Kato, T., Matsumura, T., Heller, T., Saito, S., Sapp, R.K., Murthy, K., Wakita, T. & Liang, T.J. (2007). Production of infectious hepatitis C virus of various genotypes in cell cultures. Journal of Virology 81, 4405-4411.
311. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.G., Mizokami, M., Bartenschlager, R. & Liang, T.J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine 11, 791-796.
312. Rosen, H.R. & Martin, P. (2000). Hepatitis B and C in the liver transplant recipient. Seminars in Liver Disease 20, 465-480.
313. Bailey, J. (2005). Non-human primates in medical research and drug development: A critical review. Biogenic Amines 19, 235-256.
314. Combes, R.D., Berridge, T., Connelly, J., Eve, M.D., Garner, R.C., Toon, S. & Wilcox, P. (2003). Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. European Journal of Pharmaceutical Sciences 19, 1-11.
315. NCRR (undated). Chimpanzee Management Program. Bethesda, MD, USA: NCRR. Available at: http://www.ncrr.nih.gov/comparative-medicine/chimpanzee- management-program (Accessed 17.08.10).
316. Kremsdorf, D. & Brezillon, N. (2007). New animal models for hepatitis C viral infection and pathogenesis studies. World Journal of Gastroenterology 13, 2427-2435.
317. Wu, G.Y., Konishi, M., Walton, C.M., Olive, D., Hayashi, K. & Wu, C.H. (2005). A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128, 1416-1423.
318. Ilan, E., Arazi, J., Nussbaum, O., Zauberman, A., Eren, R., Lubin, I., Neville, L., Ben-Moshe, O., Kischitzky, A., Litchi, A., Margalit, I., Gopher, J., Mounir, S., Cai, W., Daudi, N., Eid, A., Jurim, O., Czerniak, A., Galun, E. & Dagan, S. (2002). The hepatitis C virus (HCV)-Trimera mouse: A model for evaluation of agents against HCV. Journal of Infectious Diseases 185, 153-161.
319. Ilan, E., Eren, R., Lubin, I., Nussbaum, O., Zauberman, A. & Dagan, S. (2002). The Trimera mouse: A system for generating human monoclonal antibodies and modeling human diseases. Current Opinion in Molecular Therapeutics 4, 102-109.
320. Kneteman, N.M., Weiner, A.J., O'Connell, J., Collett, M., Gao, T., Aukerman, L., Kovelsky, R., Ni, Z.J., Zhu, Q., Hashash, A., Kline, J., Hsi, B., Schiller, D., Douglas, D., Tyrrell, D.L. & Mercer, D.F. (2006). Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43, 1346-1353.
321. Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y., Kimura, S., Miyamura, T. & Koike, K. (1998). The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 4, 1065-1067.
322. Bukh, J., Engle, R.E., Govindarajan, S. & Purcell, R.H. (2008). Immunity against the GBV-B hepatitis virus in tamarins can prevent productive infection following rechallenge and is long-lived. Journal of Medical Virology 80, 87-94.
323. Woollard, D.J., Haqshenas, G., Dong, X., Pratt, B.F., Kent, S.J. & Gowans, E.J. (2008). Virus-specific T-cell immunity correlates with control of GB virus B infection in marmosets. Journal of Virology 82, 3054-3060.
324. Nam, J.H., Faulk, K., Engle, R.E., Govindarajan, S., St Claire, M. & Bukh, J. (2004). In vivo analysis of the 3′ untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: Persistent infection in a transfected tamarin. Journal of Virology 78, 9389-9399.
325. Lanford, R.E., Chavez, D., Notvall, L. & Brasky, K.M. (2003). Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology 311, 72-80.
326. Xie, Z.C., Riezu-Boj, J.I., Lasarte, J.J., Guillen, J., Su, J.H., Civeira, M.P. & Prieto, J. (1998). Transmission of hepatitis C virus infection to tree shrews. Virology 244, 513-520.
327. US Government Printing Office (2007). Transportation, sale, and handling of certain animals. In Animal Welfare Act as Amended, pp. 2131-2159. Washington, DC, USA: Government Printing Office. Available at: http://frwebgate.access.gpo. gov/cgi-bin/usc.cgi?ACTION=BROWSE&TITLE= 7USCC54 (Accessed 17.08.10).
328. Humane Research Council (2005). U.S. Public Opinion of Chimpanzee Research, Support for a Ban, and Related Issues. Prepared for the New England Anti-Vivisection Society. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.release chimps.org/2006/06/20/poll- reveals-americansagreechimpanzees-in-laboratories-for-more-than- 10-years-should-be-retired (Accessed 04.02.10).
329. Forns, X., Payette, P.J., Ma, X., Satterfield, W., Eder, G., Mushahwar, I.K., Govindarajan, S., Davis, H.L., Emerson, S.U., Purcell, R.H. & Bukh, J. (2000). Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32, 618-625.
330. Capone, S., Zampaglione, I., Vitelli, A., Pezzanera, M., Kierstead, L., Burns, J., Ruggeri, L., Arcuri, M., Cappelletti, M., Meola, A., Ercole, B.B., Tafi, R., Santini, C., Luzzago, A., Fu, T-M., Colloca, S., Ciliberto, G., Cortese, R., Nicosia, A., Fattori, E. & Folgori, A. (2006). Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. Journal of Immunology 177, 7462-7471.